{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:42:17Z","timestamp":1792291337379,"version":"4.4.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Carriers of cytochrome 2C19 (CYP2C19) loss-of-function (LoF) alleles treated with clopidogrel have impaired drug metabolism, resulting in reduced active metabolite levels, high platelet reactivity (HPR), and an increased risk of thrombotic events. Several alternative antiplatelet therapies have been proposed to overcome HPR in these patients, but their comparative effects remain poorly explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Randomized controlled trials (RCTs) comparing different oral antiplatelet therapies in carriers of CYP2C19 LoF alleles undergoing percutaneous coronary interventions (PCI) were included. A frequentist network meta-analysis was conducted to estimate mean difference (MD) or odds ratios and 95% confidence intervals (CI). The primary outcome was platelet reactivity assessed by VerifyNow and reported as P2Y12 reaction unit (PRU). The secondary outcome was the rate of HPR. Standard dose of clopidogrel (75\u00a0mg daily) was used as a reference treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 12 RCTs testing 6 alternative strategies (i.e. clopidogrel 150\u00a0mg, prasugrel 3.75\u00a0mg, 5\u00a0mg, and 10\u00a0mg, ticagrelor 90\u00a0mg bid, and adjunctive cilostazol 100\u00a0mg bid) were included in the network. Compared with standard-dose clopidogrel, the greatest reduction in PRU was observed with prasugrel 10\u00a0mg (MD \u2212127.91; 95% CI \u2212141.04; \u2212114.78) and ticagrelor 90\u00a0mg bid (MD \u2212124.91; 95% CI \u2212161.78; \u221288.04), followed by prasugrel 5\u00a0mg (MD \u221276.33; 95% CI \u221298.01; \u221254.65) and prasugrel 3.75\u00a0mg (MD \u221273.00; 95% CI \u2212100.28; \u221245.72). Among other strategies, adjunctive cilostazol (MD \u221242.64; 95% CI \u221264.72; \u221220.57) and high-dose clopidogrel (MD \u221232.11; 95% CI \u221251.33; \u221212.90) were associated with a modest reduction in PRU compared with standard-dose clopidogrel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among carriers of CYP2C19 LoF alleles undergoing PCI, standard-dose prasugrel or ticagrelor are most effective in reducing platelet reactivity, while double-dose clopidogrel and additional cilostazol showed modest effects. Reduced-dose of prasugrel may represent a balanced strategy to overcome HPR without a significant increase in bleeding. The clinical implications of these pharmacodynamic findings warrant further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae036","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T20:53:25Z","timestamp":1715720005000},"page":"526-536","source":"Crossref","is-referenced-by-count":18,"title":["Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola 48023 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-7242","authenticated-orcid":false,"given":"Giovanni","family":"Occhipinti","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic, Cardiovascular Clinic Institute, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-4278","authenticated-orcid":false,"given":"Stefano","family":"Benenati","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Interna e Specialit\u00e0 Mediche (DIMI), University of Genoa , Genoa 16126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Laborante","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ortega-Paz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine , Jacksonville, FL 32209 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine , Jacksonville, FL 32209 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[{"name":"Dipartimento di MedicinaTraslazionale, Universit\u00e0 del Piemonte Orientale , Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3261","authenticated-orcid":false,"given":"Roberto","family":"Nerla","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola 48023 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castriota","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola 48023 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Latina 04100 ,","place":["Italy"]},{"name":"Department of AngioCardioNeurology, IRCCS Neuromed \u2013 Istituto Neurologico Mediterraneo Pozzilli , Pozzilli 86077 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Latina 04100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Latina 04100 ,","place":["Italy"]},{"name":"Department of AngioCardioNeurology, IRCCS Neuromed \u2013 Istituto Neurologico Mediterraneo Pozzilli , Pozzilli 86077 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Dipartimento di MedicinaTraslazionale, Universit\u00e0 del Piemonte Orientale , Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024100407363437000_bib1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"2024100407363437000_bib2","first-page":"150","article-title":"Comparative efficacy and safety of oral P2Y12","volume":"142","author":"Navarese","year":"2020","journal-title":"Inhibit Acute Coronary Syndr"},{"key":"2024100407363437000_bib3","doi-asserted-by":"crossref","first-page":"e007811","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2024100407363437000_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","article-title":"Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations","volume":"14","author":"Galli","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024100407363437000_bib5","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"2024100407363437000_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"2024100407363437000_bib7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"2024100407363437000_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2024100407363437000_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","article-title":"ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024100407363437000_bib10"},{"key":"2024100407363437000_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2024100407363437000_bib12","first-page":"e24","article-title":"Monitoring antiplatelet therapy: where are we now?","volume":"24","author":"Marcucci","year":"2023","journal-title":"J Cardiovasc Med (Hagerstown, Md)"},{"key":"2024100407363437000_bib13"},{"key":"2024100407363437000_bib14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"2024100407363437000_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijcard.2010.12.083","article-title":"The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial)","volume":"157","author":"Ari","year":"2012","journal-title":"Int J Cardiol"},{"key":"2024100407363437000_bib16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2024100407363437000_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/clc.20884","article-title":"Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance","volume":"34","author":"Wang","year":"2011","journal-title":"Clin Cardiol"},{"key":"2024100407363437000_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1160\/TH13-10-0874","article-title":"A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry","volume":"112","author":"Mayer","year":"2014","journal-title":"Thromb Haemostasis"},{"key":"2024100407363437000_bib19","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"2024100407363437000_bib20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"2024100407363437000_bib21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024100407363437000_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"2024100407363437000_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet (London, England)"},{"key":"2024100407363437000_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/L15-5144-2","article-title":"The PRISMA extension statement","volume":"163","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024100407363437000_bib25","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"key":"2024100407363437000_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcin.2010.12.011","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping","volume":"4","author":"Alexopoulos","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2024100407363437000_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1160\/TH13-03-0263","article-title":"Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways","volume":"110","author":"Braun","year":"2013","journal-title":"Thromb Haemost"},{"key":"2024100407363437000_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2020.02.009","article-title":"Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic testing","volume":"5","author":"Franchi","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2024100407363437000_bib29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1160\/TH13-10-0891","article-title":"The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease","volume":"112","author":"Gurbel","year":"2014","journal-title":"Thromb Haemostasis"},{"key":"2024100407363437000_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2020.01.058","article-title":"Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial)","volume":"305","author":"Jin","year":"2020","journal-title":"Int J Cardiol"},{"key":"2024100407363437000_bib31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcin.2010.12.010","article-title":"Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype","volume":"4","author":"Kim","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2024100407363437000_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jjcc.2015.07.019","article-title":"Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"68","author":"Ogawa","year":"2016","journal-title":"J Cardiol"},{"key":"2024100407363437000_bib33","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet (London, England)"},{"key":"2024100407363437000_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2217\/pgs.14.17","article-title":"Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: a pilot study","volume":"15","author":"Rossi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"2024100407363437000_bib35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehp157","article-title":"Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease","volume":"30","author":"Varenhorst","year":"2009","journal-title":"Eur Heart J"},{"key":"2024100407363437000_bib36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/hrt.2010.216499","article-title":"Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial","volume":"97","author":"Park","year":"2011","journal-title":"Heart"},{"key":"2024100407363437000_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jcin.2008.09.005","article-title":"The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial","volume":"1","author":"Gladding","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"2024100407363437000_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tcm.2021.12.007","article-title":"Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention","volume":"33","author":"Galli","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"2024100407363437000_bib39","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"2024100407363437000_bib40","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/eurheartj\/ehad362","article-title":"Personalised antiplatelet therapies for coronary artery disease: what the future holds","volume":"44","author":"Capodanno","year":"2023","journal-title":"Eur Heart J"},{"key":"2024100407363437000_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy: a meta-analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2024100407363437000_bib42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2024100407363437000_bib43","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"2024100407363437000_bib44","first-page":"447","article-title":"Antithrombotic therapy for secondary prevention in patients with non-cardioembolic stroke or transient ischemic attack: a systematic review","volume":"11","author":"Tornyos","year":"2021","journal-title":"Life (Basel)"},{"key":"2024100407363437000_bib45","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"2024100407363437000_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024100407363437000_bib47","doi-asserted-by":"publisher","first-page":"pvae019","DOI":"10.1093\/ehjcvp\/pvae019","article-title":"De-escalation versus shortening of DAPT","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024100407363437000_bib48","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","article-title":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis","volume":"44","author":"Kang","year":"2023","journal-title":"Eur Heart J"},{"key":"2024100407363437000_bib49","doi-asserted-by":"crossref","first-page":"e000068","DOI":"10.1136\/openhrt-2014-000068","article-title":"Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials","volume":"1","author":"Bangalore","year":"2014","journal-title":"Open Heart"},{"key":"2024100407363437000_bib50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae036\/58780608\/pvae036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/6\/526\/59582099\/pvae036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/6\/526\/59582099\/pvae036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:37:02Z","timestamp":1728027422000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/6\/526\/7675497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae036","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,16]]}}}